229980-47-6

Upstream product

• 67-56-1 methanol 
• 49803-18-1 2-(4-bromophenoxy)-2-methylpropanoyl chloride 
• 7472-69-7 2-(4-bromophenoxy)-2-methylpropanoic acid 
• 106-41-2 4-bromo-phenol 

Downstream Products

• 1350846-97-7 methyl 2-[4-(2-phthalimidoethen-2-yl)phenoxy]-2-methylpropanoate 
• 627095-94-7 2-(4-{2-[N-(heptyl)-N-(benzoxazol-2-yl)amino]ethyl}phenoxy)-2-methylpropanoic acid 
• 1350846-81-9 methyl 2-[4-(2-heptanoylaminoethyl)phenoxy]-2-methylpropanoate 
• 1350846-89-7 methyl 2-[4-(2-phthalimidoethyl)phenoxy]-2-methylpropanoate 
• 190182-03-7 methyl 2-[4-(2-aminoethyl)phenoxy]-2-methylpropanoate 
• 1350846-93-3 methyl 2-[4-(2-heptylaminoethyl)phenoxy]-2-methylpropanoate 
• 1350846-85-3 methyl 2-(4-{2-[N-(heptyl)-N-(benzoxazol-2-yl)amino]ethyl}phenoxy)-2-methylpropanoate 

Relevant academic research and scientific papers

Synthesis, characterization and biological evaluation of ureidofibrate-like derivatives endowed with peroxisome proliferator-activated receptor activity

A series of ureidofibrate-like derivatives was prepared and assayed for their PPAR functional activity. A calorimetric approach was used to characterize PPARγ-ligand interactions, and docking experiments and X-ray studies were performed to explain the obs

MORPHOLINE COMPOUND

A compound represented by the formula (1) wherein ring A is aryl optionally having substituent(s) and the like; ring B is arylene optionally having substituent(s) and the like; m=0-2; n=1-5; X is a bond and the like; Y is a bond and the like; and Z is hydrogen atom and the like or a pharmaceutically acceptable salt thereof, and a hydrate or solvate thereof have affinity for CCR3, and can be pharmaceutical products for the treatment and/or prophylaxis of immune or inflammatory diseases.

INDOLES USEFUL IN THE TREATMENT OF INFLAMMATION

There is provided a compound of formula: (I), wherein X, R1, R2, R3, R4, R5 and R6 have meanings given in the description, and pharmaceutically-acceptable salts thereof, which compounds are useful in the treatment of diseases in which inhibition of the activity of microsomal prostaglandin E synthase-1 is desired and/or required, and particularly in the treatment of inflammation.